---

• Elbe A, Foerster KI, Blank A, Rose P, Burhenne J, Haefeli WE, Mikus G. Evaluation of CYP2C19 activity using microdosed oral omeprazole in humans. Eur J Clin Pharmacol 2022;78:975-987.
• Grass J, Rose P, Burhenne J, Blank A, Haefeli WE, Mikus G. Absolute Bioavailability of Microdosed Midazolam After Buccal Administration Is Dependent on Buccal Exposure Time. J Clin Pharmacol 2021;61:472-479.
• Mahmoudi M, Foerster KI, Burhenne J, Weiss J, Mikus G, Haefeli WE. Application of Microdosed Intravenous Omeprazole to Determine Hepatic CYP2C19 Activity. J Clin Pharmacol 2021;61:789-798.
• Foerster KI, Burhenne J. Microdosing drugs: a versatile technique to detect and assess drug-drug interactions. Expert Opin Drug Metab Toxicol 2020;16:447-448.
• Mikus G, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE. Application of a microdosed cocktail of 3 oral factor Xa inhibitors to study drug-drug interactions with different perpetrator drugs. Br J Clin Pharmacol 2020;86:1632-1641.
• Geist M, Bardenheuer H, Burhenne J, Mikus G. Alteration of drug-metabolizing enzyme activity in palliative care patients: microdosed assessment of cytochrome P450 3A. Palliat Med 2019;33:850-855.
• Hohmann N, Blank A, Burhenne J, Suzuki Y, Mikus G, Haefeli WE. Simultaneous phenotyping of CYP2E1 and CYP3A using oral chlorzoxazone and midazolam microdoses. Br J Clin Pharmacol 2019;85:2310-2320.
• Kiene K, Hayasi N, Burhenne J, Uchitomi R, Sünderhauf C, Schmid Y, Haschke M, Haefeli WE, Krähenbühl S, Mikus G, Inada H, Huwyler J. Microdosed midazolam for the determination of cytochrome P450 3A activity: development and clinical evaluation of a buccal film. Eur J Pharm Sci 2019;135:77-82.
• Mikus G, Foerster KI, Schaumaeker M, Lehmann ML, Burhenne J, Haefeli WE. Microdosed Cocktail of Three Oral Factor Xa Inhibitors to Evaluate Drug-Drug Interactions with Potential Perpetrator Drugs. Clin Pharmacokinet 2019;58:1155-1163.
• Vay M, Sauter M, Mikus G, Burhenne J. Quantification of microdosed oral yohimbine and its major metabolite in human plasma in the picogram range. Bioanalysis 2019;11:1459-1467.
• Witt L, Suzuki Y, Hohmann N, Mikus G, Haefeli WE, Burhenne J. Ultrasensitive quantification of the CYP2E1 probe chlorzoxazone and its major metabolite 6-hydroxychlorzoxazone in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry after chlorzoxazone microdosing. J Chromatogr B Analyt Technol Biomed Life Sci 2016;1027:207-13.
• Hohmann N, Kocheise F, Carls A, Burhenne J, Haefeli WE, Mikus G. Midazolam microdose to determine systemic and pre-systemic metabolic CYP3A activity in humans. Br J Clin Pharmacol 2015;79:278-85.
• Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE. A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther 2013;93:564-71.
• Burhenne J, Halama B, Maurer M, Riedel KD, Hohmann N, Mikus G, Haefeli WE. Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1'-hydroxymidazolam in human plasma using ultra performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem 2012;402:2439-50.